Study: Blood stem cells can eliminate leukemia stem cells | Stem cells could lead to better skin grafts, Canadian researchers say | Delivery of clot-busting drug via surgery has benefits, study finds
Web Version
 
 
February 11, 2013
AABB SmartBrief
News for the transfusion medicine and cellular therapy community
SIGN UP|FORWARD|ARCHIVE

Top StorySponsored By
Study: Blood stem cells can eliminate leukemia stem cells
Maintaining a high level of functioning hematopoietic stem cells -- which produce immune cells, red blood cells and platelets -- may be enough to eliminate leukemia stem cells, according to a study published in the Journal of the Royal Society Interface. Researchers used computer modeling and simulations to test the effect of an HSC-promoting environment on LSCs. Maintaining an environment conducive to healthy cells may be a better approach to eradicating leukemia cells than focusing on cancerous cells directly, researchers said. Oncology Nurse Advisor online (2/8)
Share: LinkedInTwitterFacebookGoogle+Email
Variety is the spice of life.
That's why Quotient sources cells from US, Europe and Asia for its new to the market antibody screens and ID panels, helping you rule out and rule in antibodies. GPOs must like variety too, because Quotient has new contracts with Premier, Amerinet and GSA, saving you money. Find out how the one company focused on manual testing can serve you in 2013 and beyond.
Advertisement
 
Science & HealthSponsored By
Stem cells could lead to better skin grafts, Canadian researchers say
University of Calgary researchers are experimenting with stem cells to create skin grafts that perform more like natural skin. Trauma patients, cancer patients and burn survivors would benefit from better split-thickness skin grafts, researchers said. The investigators aim to create skin grafts that promote healing and allow the growth of follicles. CBC.ca (Canada) (2/7)
Share: LinkedInTwitterFacebookGoogle+Email
 
Delivery of clot-busting drug via surgery has benefits, study finds
Researchers tracked 96 patients with intracerebral hemorrhage and found that those who underwent surgery to receive the clot-busting drug tissue plasminogen activator, or tPA, directly in their brains recovered faster than those who were treated with standard therapy. Patients who received tPA were discharged an average of 38 days earlier, and their blood clots dissolved faster. The study appears in the journal Stroke. HealthDay News (2/7)
Share: LinkedInTwitterFacebookGoogle+Email
Study: ICU infections curbed by daily chlorhexidine wipedowns
Giving ICU patients a daily bath using chlorhexidine washcloths led to a 23% lower rate of multi-drug resistant organism acquisition, researchers reported in the New England Journal of Medicine. The chlorhexidine baths also reduced the rate of hospital-acquired bloodstream infections by 28%. MedPage Today (free registration) (2/6)
Share: LinkedInTwitterFacebookGoogle+Email
Want More CME/CE Credit from AABB?
Now it's even easier to accomplish your training needs and earn CME/CE credits. Convenient and accessible anytime, the AABB Live Learning Center offers quick access to essential Annual Meeting and audioconference content. Most products offer CME/CE tracking and attendance certification. Click here to get started!
Advertisement
 
Hot Topics
Emerging Trends
More than 60 ACOs establish national group
The National Association of ACOs has been established through a collaboration of more than 60 accountable care organizations. The group's mission includes promoting uniform performance and quality measures, as well as educating the public on the importance of accountable care. BeckersHospitalReview.com (2/8)
Share: LinkedInTwitterFacebookGoogle+Email
Industry News & Practice
PPD adds to screening facilities in Brussels, Singapore
PPD is offering a greater range of infectious disease screening at its facilities in Singapore and Brussels after expansions there. The laboratories will provide the same range of microbiology testing services as PPD's Highland Heights, Ky., lab. The company specializes in studies of infectious diseases. Star-News (Wilmington, N.C.) (2/8)
Share: LinkedInTwitterFacebookGoogle+Email
Biogen may get boost from hemophilia drug data
Recent data from a late-stage study showed promising results for Biogen Idec's two hemophilia drugs, Factor VIII and Factor IX, and FDA approval could mean more jobs at the company. Biogen has filed a regulatory review of Factor IX and is planning to file for Factor VIII in the first half of the year. American City Business Journals/Raleigh/Durham, N.C./Triangle BizBlog (2/8)
Share: LinkedInTwitterFacebookGoogle+Email
Hospitals recognized for use of nursing quality data
The American Nurses Association honored the six recipients of the National Database of Nursing Quality Indicators Award for Outstanding Nursing Quality, including Robert Wood Johnson University Hospital in New Brunswick, N.J. Of the more than 1,900 hospitals considered for the award, six "demonstrated superior results and sustained improvement in patient outcomes that are tied to the quality of nursing services and nurse work environment factors," the group said. The other recipients are Akron Children's Hospital Mahoning Valley of Boardman, Ohio; Craig Hospital of Englewood, Colo.; Rose Medical Center of Denver; Sharp Mesa Vista Hospital of San Diego; and St. Francis Hospital -- The Heart Center in Roslyn, N.Y. Nurse.com (2/7)
Share: LinkedInTwitterFacebookGoogle+Email
The Buzz
Registration Now Open - April 9, 2013 PACT Workshop
?Developing Cellular Therapies: From Preclinical Safety to Clinical Evaluation?. Hosted by University of Wisconsin, Waisman Biomanufacturing (WB), Madison, WI. No charge for attendance. Click here for more details.
 
Government & Regulatory
President wants Tavenner to continue leading CMS
President Barack Obama has renominated Marilyn Tavenner to serve as CMS administrator. Tavenner, who succeeded Don Berwick, has been working as acting administrator since her first nomination. The Hill/Healthwatch blog (2/7)
Share: LinkedInTwitterFacebookGoogle+Email
Senate bill takes aim at 2.3% medical device tax
A bipartisan bill that would repeal the 2.3% medical device tax has been introduced in the Senate. Industry leaders and lawmakers in favor of the repeal said the tax will threaten job growth and medical innovation. "In order to compete in the global economy, our medical device businesses need a level playing field," said Sen. Amy Klobuchar, D-Minn. Reuters (2/7)
Share: LinkedInTwitterFacebookGoogle+Email
Celgene's multiple myeloma drug Pomalyst wins FDA approval
The FDA has approved Celgene's Pomalyst, or pomalidomide, as treatment for patients with multiple myeloma who have stopped responding to other therapies. Pomalyst is intended to strengthen the immune system in blocking and eliminating cancer cells. The drug's label will include a warning that it can cause clots and that it should not be used by pregnant women because of the risk for birth defects. HealthDay News (2/8), Reuters (2/8)
Share: LinkedInTwitterFacebookGoogle+Email
FDA gives orphan-drug designation to Apogenix's MDS drug Apocept
The FDA granted orphan-drug status to Apocept, or APG101, Apogenix's investigational drug for myelodysplastic syndromes. The company said it launched an early-stage trial in Germany to assess Apocept's safety, efficacy and tolerability in MDS patients. Pharmaceutical Business Review Online (2/8)
Share: LinkedInTwitterFacebookGoogle+Email
Association News
Upcoming AABB audioconference to focus on characteristics of an effective team
Tomorrow's AABB audioconference will review characteristics of an effective team. It also will discuss how teamwork can help organizations achieve specific goals. Learn more.
Share: LinkedInTwitterFacebookGoogle+Email
Who's Hiring?
Position TitleCompany NameLocation
Donor Collections DirectorBlood Centers of the PacificUS - CA - San Francisco
Medical Technologist CLS - Cord Blood ProgramSan Diego Blood BankUS - CA - San Diego
CLINICAL LABORATORY SCIENTISTBlood Centers of the PacificUS - CA - San Francisco
Click here to view more job listings.
 
SmartQuote
The only man I know who behaves sensibly is my tailor; he takes my measurements anew each time he sees me. ... The rest go on with their old measurements and expect me to fit them."
-- George Bernard Shaw,
Irish playwright
Share: LinkedInTwitterFacebookGoogle+Email
Learn more about AABB® ->Homepage | Join AABB | Conferences | Marketplace | AABB CareerLink
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
 
Editor:  Tom Parks
Managing Editor:  Amanda Horn
Advertising Manager:  Annette Bacchus
  M: 240.333.6604
Jobs Contact:  Jackie Basso
  P: 202.407.7871
 
 

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2014 SmartBrief, Inc.®
Privacy policy |  Legal Information